Artiva Biotherapeutics
ARTV
NASDAQ
IPO2024
about ARTV
Artiva Biotherapeutics is a biopharmaceutical company dedicated to creating cutting-edge treatments for autoimmune disorders through its lead product, an IL-17A/F inhibitor named SKYLCAT, aimed at reducing inflammation and addressing patient needs.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $5.59 | $7.36 | $5.14 | $146.80M | 100.33M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.87 | n/a | n/a | 0% | 0% | 0% |